Long-term follow-up of patients with systemic lupus erythematosus at Brest CHRU
Official title: Follow-up of the Systemic Lupus Erythematosus Cohort as Part of the Multidisciplinary Consultation at Brest CHRU
Run by University Hospital, Brest · NCT06551389 · Data updated 2026-11-12
This study follows patients with systemic lupus erythematosus to see how their condition changes over time and to gather information that can help improve treatment and understanding of the disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | University Hospital, Brest Academic / other |
| Locations | 1 site (Brest) |
| Status | Recruiting |
| Started | October 13, 2020 |
| Main results expected | April 2035 |
| Study ends | April 2035 |
| Registry record updated | June 25, 2026 |
| Trial ID | NCT06551389 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 years old who are receiving care at the multidisciplinary consultation for systemic lupus erythematosus.
✕Probably not a fit
Patients who oppose participation in the study will not benefit from this initiative.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to follow a cohort of patients with systemic lupus erythematosus (SLE) who are part of a multidisciplinary consultation at the University Hospital of Brest. The study will collect standardized data on the clinical, biological, and immunological patterns of SLE over time, involving specialists from various fields such as rheumatology, nephrology, and dermatology. The goal is to evaluate current practices, study the epidemiology of SLE in the region, and promote findings at both national and international levels.
Why it matters
Potential benefit: If successful, this study could enhance the understanding and management of systemic lupus erythematosus, leading to improved patient outcomes.
How similar studies have gone: Other studies focusing on multidisciplinary approaches to autoimmune diseases have shown promise, indicating that this approach may yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any patient over 18 years old of the multidisciplinary consultation Exclusion Criteria: * Opposition of patient
Where it's running
-
CHRU de Brest
Brest, France Recruiting
Study contacts
- Study coordinator: Sandrine JOUSSE-JOULIN, Rheumatologist
- Email: sandrine.jousse-joulin@chu-brest.fr
- Phone: 33 (0)2-98-34-72-64
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of anifrolumab on arterial inflammation in SLE patients
This study tests whether anifrolumab can reduce blood vessel inflammation in people with active systemic lupus erythematosus.
-
Home urine testing for people with lupus
Participants with lupus will try weekly home urine tests in addition to usual care to see if this helps monitor kidney health over a year.
-
CR-402 treatment for refractory autoimmune disease
This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.
-
ATG-201 in adults with autoimmune diseases
This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.
-
Biomarker tests in adults with lupus to see how kidney disease changes over time
Researchers will follow adults with lupus to see if blood and urine biomarkers can predict kidney involvement, flares, and treatment responses during routine care.
-
Sirolimus added to standard therapy for adults with SLE-associated immune thrombocytopenia
This trial tests whether adding sirolimus to usual treatment helps adults with SLE-related immune thrombocytopenia see their platelet counts improve.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.